Caption Management’s Cue Biopharma CUE Stock Holding History

Caption Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-357	Closed	-$28.2K	–	1289
2023 Q4	$28.2K	Hold	357	–	–	﹤0.01%	1246
2023 Q3	$24.6K	Buy	+357	New	+$34.9K	﹤0.01%	1214

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caption Management's CUE Position: Q1 2024 in Review

Caption Management sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 467 shares — an estimated $37K sold.

Caption Management first reported a position in CUE in Q2 2021 and held it in 4 quarters. The position peaked at $396K in Q3 2021. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

Caption Management reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
Caption Management sold 467 Cue Biopharma shares in Q1 2024, an estimated $37K.
Caption Management first reported a position in Cue Biopharma in Q2 2021 and held it in 4 quarters.
Caption Management's Cue Biopharma position peaked at $396K in Q3 2021.
74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.